Safety and secondary pharmacology: successes, threats, challenges and opportunities.
This review summarises the lecture of Dr Tim Hammond, recipient of the Distinguished Service Award of the Safety Pharmacology Society, given on 20 September 2007 in Edinburgh. The lecture discussed the rationale behind the need for optimal non-clinical Safety and Secondary Pharmacology testing; the evolution of Safety and Secondary Pharmacology over the last decade; its impact on drug discovery and development; the value of adopting an integrated risk assessment approach; the translation of non-clinical findings to humans and finally the future challenges and opportunities facing these disciplines.
Valentin
Jean-Pierre
JP
Safety Assessment UK, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, United Kingdom. jean-pierre.valentin@astrazeneca.com
Hammond
Tim
T
D000818:Animals; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D010600:Pharmacology / Q000639:trends; D051381:Rats; D018675:Toxicity Tests / Q000191:economics / Q000379:methods* / Q000639:trends*